Standard preventive medicine is designed to detect disease, not prevent it. The difference between those two goals is where most people fall through the cracks. This case illustrates exactly how — and what catching it early actually looks like.
Case:
44 year old male attorney. Referred by his internist for a second opinion on mild memory concerns. His internist’s note read: “Full metabolic panel, CBC, thyroid — all normal. Patient reassured.” He had been told his labs were fine twice in the past three years. He continued to have symptoms.
Labs:
Fasting glucose: 94 mg/dL. (Normal range. Internist stopped here.)
Fasting insulin: 19 uIU/mL. (Optimal 2-6. Significant insulin resistance.)
HOMA-IR: 4.4. (Above 2.0 = insulin resistant. Not tested prior.)
APOB: 118 mg/dL. (Optimal < 80. Standard LDL-C was “normal”.)
Homocysteine: 17 umol/L. (Above 14 = elevated dementia risk. Not tested prior.)
Vitamin B12: 224 pg/mL. (Low normal. Driving homocysteine elevation.)
His fasting glucose was 94 — technically normal. But his fasting insulin was 19 uIU/mL, indicating his pancreas was working enormously hard to keep glucose normal. He had insulin resistance completely invisible to a glucose-only screen. His ApoB was elevated while standard LDL-C appeared fine — a discordance that occurs specifically in insulin-resistant patients and significantly understates cardiovascular risk.
What I recommended:
B12 1000 mcg daily sublingual — to normalize homocysteine within 8-12 weeks. Sublingual chosen for bioavailability given his borderline B12 suggested possible absorption issues.
Time-restricted eating (16:8 window) combined with carbohydrate reduction — to address insulin resistance through the most evidence-based non-pharmacological combination. Target: HOMA-IR below 1.5 at 12 week reassessment.
Zone 2 cardio 3 times weekly, 40 minutes per session — the most potent lifestyle intervention for improving insulin sensitivity and VO2 max simultaneously.
Reassess ApoB at 12 weeks with the expectation that metabolic improvement would improve lipid particle quality. If ApoB remained elevated, discuss statin therapy with his internist.
The Outcome:
At 12 weeks: fasting insulin dropped from 19 to 7 uIU/mL. HOMA-IR fell from 4.4 to 1.6. Homocysteine normalized to 9 umol/L. ApoB dropped from 118 to 84 mg/dL. His memory complaints had largely resolved — consistent with reduced neuroinflammatory burden and improved hippocampal insulin signaling. No medication was required beyond B12.
From the Neurologist:
This patient was told he was fine three times. He had two correctable, early drivers of neurodegeneration — insulin resistance and elevated homocysteine — that his standard labs did not detect. This highlights the gap between standard preventive medicine and longevity medicine.
Call to Action:
If your last blood panel did not include fasting insulin, ApoB, and homocysteine, you have not had a longevity-oriented evaluation. These tests help catch what matters while it is still reversible.
Disclaimer: The content published in The Brain Capsule is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider before making any changes to your health, diet, or wellness routine. The views expressed are based on current research and are subject to change as new evidence emerges.